EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

EKF Diagnostics provides a further update regarding its forthcoming changes to the board of directors of the Company and its planned, final performance related payments to the Company’s Chief Executive Officer and Finance Director. 

19th May 2021

Strong trading continues into Q2, upgrading full year expectations. Growth Plans & Managed Succession

Trellus Health plc proposed placing, subscription and restricted offer.

Further to the announcement on 23 April 2021.

30th Apr 2021

Adam Reynolds, Non-Executive Director, has sold a total of 500,000 ordinary shares.

29th Apr 2021

EKF Diagnostics Holdings plc confirms that the Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting have now been published.

The Board of EKF Diagnostics Holdings plc (AIM: EKF) has been informed that on 20 April 2021 Christopher Mills, Chairman, sold a total of 3,963,591 ordinary shares of 1 pence each in the Company (“Ordinary Shares”) at an average price of 80 pence per Ordinary Share.

30th Mar 2021

Final results for the year ended 31 December 2020

Further to the announcement on 5 August 2020.